Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antiinfective agent stubs
Sangivamycin
Другие языки:

    Sangivamycin

    Подписчиков: 0, рейтинг: 0
    Sangivamycin
    Sangivamycin.svg
    Identifiers
    • 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carboxamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    ChEBI
    ChEMBL
    ECHA InfoCard 100.162.068
    Chemical and physical data
    Formula C12H15N5O5
    Molar mass 309.28 g·mol−1
    3D model (JSmol)
    • C1=C(C2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)C(=O)N
    • InChI=1S/C12H15N5O5/c13-9-6-4(10(14)21)1-17(11(6)16-3-15-9)12-8(20)7(19)5(2-18)22-12/h1,3,5,7-8,12,18-20H,2H2,(H2,14,21)(H2,13,15,16)/t5-,7-,8-,12-/m1/s1
    • Key:OBZJZDHRXBKKTJ-JTFADIMSSA-N

    Sangivamycin is a natural product originally isolated from Streptomyces rimosus, which is a nucleoside analogue. It acts as an inhibitor of protein kinase C. It has antibiotic, antiviral and anti-cancer properties and has been investigated for various medical applications, though never approved for clinical use itself. However, a number of related derivatives continue to be researched.

    Oyagen, a biotechnology company, has been developing sangivamycin or OYA1, which showed efficacy against Ebola infections, as a broad spectrum antiviral for COVID-19.Tonix Pharmaceuticals licensed OYA1 from Oyagen in April 2021 to develop it for the treatment of COVID-19 and it is now called TNX-3500.

    See also


    Новое сообщение